Mayo Clinic and Stanford Medicine unveiled a blood test designed to chart the tumor “neighborhood” by profiling the tumor microenvironment more directly than conventional liquid biopsy approaches. The method aims to improve therapy response prediction by capturing signaling and cellular context associated with how tumors behave. The collaboration positions the test for broader precision-oncology workflows where clinicians need actionable, minimally invasive biomarkers. The reported approach focuses on interpreting systemic signals that reflect the local ecosystem around cancer cells.